How long is too long? Association of time delay to successful reperfusion and ventricular function outcome in acute myocardial infarction: The case for thrombolytic therapy before planned angioplasty for acute myocardial infarction

American Heart Journal

Volumn 144, Issue 3, 2002, Pages 456-462

  Lundergan, Conor F ^a   Reiner, Jonathan S ^a   Ross, Allan M ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY REPERFUSION; DOUBLE BLIND PROCEDURE; FEMALE; HEART VENTRICLE FUNCTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SYMPTOM; TIME;

EID: 0036733551     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.124868     Document Type: Article

References (27)

1. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
2. Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study
3. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
4. Prehospital-initiated vs hospital-initiated thrombolytic therapy: The Myocardial Infarction Triage and Intervention Trial
5. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty
6. Time to therapy and salvage in myocardial infarction
7. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction: The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes
8. Coronary angioplasty with or without stent implantation for acute myocardial infarction
9. Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction
10. Adverse outcomes accompanying primary angioplasty (PTCA) for acute myocardial infarction (AMI): Dangers of delay
11. For the myocardial infarction triage and intervention investigators: A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction
12. Clinical experience with primary percutaneous transluminal angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
13. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
14. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
15. New plasminogen activators: A clinical review
16. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial
17. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
18. The use of biplane angiography for the measurement of left ventricular volumes in man
19. Left ventricular segmental wall motion: A new method using local direction information
20. Extended mortality benefit of early postinfarction reperfusion
21. Hospital delay in achieving reperfusion with direct PTCA in GUSTO-IIb: Relationship to 30-day mortality
22. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 10A dose-ranging trial
23. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial
24. Relationship of symptom onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction
25. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour